BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, August 3, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Evry-Synaptive-12-10.png

Synaptive Medical announces close of $25M preferred share financing to expand global footprint

Dec. 10, 2019
By David Godkin
TORONTO – Synaptive Medical Inc. has completed the first round of a new preferred equity investment totaling $25 million led by Guelph-Ontario-based Linamar Corp., which also entered into a manufacturing agreement with Synaptive, and Calgary’s Audible Capital Corp.
Read More
Hong Kong stock market illustration

Prerevenue med-tech Venus raises $308M on HKEX

Dec. 10, 2019
By Elise Mak
BEIJING – Chinese transcatheter heart valve developer Venus Medtech (Hangzhou) Inc. on Tuesday saw its share prices jump around 20% on its debut on the Hong Kong Stock Exchange (HKEX), an excellent start for a prerevenue med-tech IPO.
Read More

Summit raising $50M, gaining majority stakeholder and dropping AIM listing

Dec. 10, 2019
By Nuala Moran
LONDON – Biotech billionaire Bob Duggan is taking a majority stake in Summit Therapeutics plc, as part of a proposed subscription and placing to raise $50 million. The scheme has to be voted through by shareholders, but assuming it is approved, Duggan will control approximately 73% of Summit’s enlarged share capital. Duggan previously invested $25 million in the company at the start of 2019, and already holds 49% of the stock.
Read More

Immunos raises $15M for multitasking immune-activating agents

Dec. 10, 2019
By Cormac Sheridan
DUBLIN – Immunos Therapeutics AG raised CHF15 million (US$15.2 million) in a series A round to move a novel immuno-oncology platform designed to turn cold tumors hot into early clinical development.
Read More

Financings for Dec. 10, 2019

Dec. 10, 2019
Biopharmas raising money in public or private financings.
Read More

Financings for Dec. 10, 2019

Dec. 10, 2019
Med-tech firms raising money in public or private financings.
Read More
Dollar sign in piggy bank

Emphasizing synergy and efficiency, EOC Pharma raises $71M series C to fight breast, gastric cancers

Dec. 10, 2019
By Elise Mak
BEIJING – EOC Pharmaceutical Group, of Shanghai, completed a series C financing round, bagging $71 million to advance its lead programs EOC-103 and EOC-315 for breast and gastric cancers. The round was led by Hangzhou Tigermed Consulting Co. Ltd. and its affiliated funds, TF Capital and Yingke PE.
Read More

Financings for Dec. 10, 2019

Dec. 10, 2019
Biopharmas in Asia-Pacific raising money in public or private financings.
Read More

Financings for Dec. 9, 2019

Dec. 9, 2019
Med-tech firms raising money in public or private financings.
Read More

Financings for Dec. 9, 2019

Dec. 9, 2019
Biopharmas raising money in public or private financings.
Read More
Previous 1 2 … 657 658 659 660 661 662 663 664 665 … 688 689 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 31, 2026.
  • HIV virus

    AIDS 2026: New targets for metabolic dysfunction despite ART

    BioWorld
    Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
  • Jingxin discloses new muscarinic and sigma receptor agonists

    BioWorld Science
    Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
  • Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors

    BioWorld Science
    Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
  • Silhouette illustration of DNA gene editing

    Death in Chinese gene-editing trial exposes ethical fault lines

    BioWorld
    The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing